Infections with rhinoviruses are the most common triggers for shortness of breath in pre-school children. The inhalation of hypertonic saline (HS) showed positive effects on the course of the disease [1, 2] . In the past, even very young bronchiolitis patients were successfully treated with slightly hypertonic saline, an approach which currently is under discussion [3, 4] .
The inhalation of hypertonic saline is seen more and more as an efficient secretolytic option in the treatment of airway diseases in children. This survey is particularly looking after age and diagnosis of the patients receiving this treatment and the clinical results which can be achieved. In this multi-center, non-interventional, retrospective investigation, 43 private doctors/hospitals in Germany and Austria evaluated data from 156 patients who received inhalation therapy with 3% HS (Mucoclear®, PARI GmbH). A questionnaire was used to assess parameters like secretolysis, cough, shortness of breath, course of the disease, absence from school or kindergarten on a scale from 1 (no effect) to 10 (very good effect). Additionally, they reported acceptance, tolerability and side effects of the treatment.
Results

Patients' Age
27% of the 156 patients receiving the 3% hypertonic saline inhalation therapy were under 1 year old; 24% were 1-3 years of age, 18% 3-5 and 20% 5-10 years of age. Remaining 11% of the children were more than 10 years old. The average assessment regarding the reduction of days off was 72%, and regarding savings of further mucolytics was 80% of the maximum number of points. 
Conclusions Literature
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The consulted Austrian and German pediatricians used the well tolerated inhalation of 3% HS successfully up to the age of 10 and beyond. Patients, especially with acute and chronic bronchitis, benefitted from symptom reduction, improved course of the disease, reduction of days-off and a decrease in additionally needed medication. The effect of the inhalation therapy with 3% HS in defined patient groups should be studied in further investigations.
Contacts: Dr. Markus Koch, Hochried 1-12, 82418 Murnau, Germany, koch@klinikhochried.de, www.klinikhochried.de Diagnoses 58% of the patients were diagnosed with bronchitis (38% acute, 20% chronic). 19% had bronchiolitis, 10% asthma, 5% croup syndrom and 3% cystic fibrosis (CF). There were also some patients with bronchiectasis, chronic rhinosinusitis, laryngotracheitis, lung hypoplasia and primary cilia dyskinesia (PCD).
Acceptance and Tolerability
The nebuliser therapy was well accepted (85%), the tolerability of the inhaled 3% saline was evaluated as very good (90%). Cough as side effect was reported in 6 of 156 cases (3.85%). 
Core Area Acute and Chronic Bronchitis
A remarkably high number of patients with bronchitis (94/156, 60%) received the inhalation therapy with 3% HS. These patients benefitted more than the average. Characteristic bronchitis symptoms like bronchial secretion, cough and shortness of breath were well influenced and rated with 68-86% of the maximum possible points. 
